Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: An immunohistochemical study in bone marrow biopsies of 67 patients

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 1, 2011, Pages 115-117

  Terpos, Evangelos ^a   Tasidou, Anna ^b   Eleftherakis Papaiakovou, Evangelos ^a   Christoulas, Dimitrios ^a   Gavriatopoulou, Maria ^a   Gkotzamanidou, Maria ^a   Roussou, Maria ^a   Kastritis, Efstathios ^a   Papadaki, Theodora ^b   Dimopoulos, Meletios Athanassios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD68 ANTIGEN; INTERFERON REGULATORY FACTOR 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; SYNDECAN 1;

ADULT; AGED; ANTIGEN EXPRESSION; B LYMPHOCYTE; BONE MARROW BIOPSY; CANCER CELL; CONFERENCE PAPER; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLAST; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; WALDENSTROEM MACROGLOBULINEMIA;

EID: 79953697699     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2011.n.024     Document Type: Conference Paper

References (10)

1. Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press. 2001.
2. Owen RG, Treon SP, Al Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:110-5. (Pubitemid 36506291)
3. Kyle RA, Benson J, Larson D, et al. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009; 9:17-8.
4. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564-9. (Pubitemid 34438817)
5. McMaster ML, Caporaso N. Waldenstrom macroglobulinaemia and IgM monoclonal gammopathy of undetermined significance: emerging understanding of a potential precursor condition. Br J Haematol 2007; 139:663-71. (Pubitemid 350115717)
6. Schop RF, Van Wier SA, Xu R, et al. 6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet 2006; 169:150-3. (Pubitemid 44382607)
7. Baldini L, Goldaniga M, Guffanti A, et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol 2005; 23:4662-8. (Pubitemid 46224068)
8. Owen RG, Parapia LA, Higginson J, et al. Clinicopathological correlates of IgM paraproteinemias. Clin Lymphoma 2000; 1:39-43.
9. Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenstrom's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993; 11:1553-8. (Pubitemid 23228262)
10. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000; 18:214-26.